International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 5 Sept - Oct 2025, pp: 820-831 www.ijprajournal.com ISSN: 2456-4494

A Comparative Review of Calcium Lysinate and Conventional Calcium Supplements in the Management of Osteoporosis: Mechanisms, Bioavailability, and Clinical Evidence

Dr. Kalpesh Ladhawala[1*], Dr. Nidhi Tanmay Shah[2], Dr. Khushal R. Shah[3], Debasish Mitra[4], Rahul Kumar Singh[5], Aadit Shah[6], Sauras Patel[7], Hetvi Patel[8]

[1]*Managing Director, WalparNutritions Limited, Kalol,Gandhinagar,Gujarat*
[2]*Co-founder & Director,WalparNutritions Limited, Kalol,Gandhinagar,Gujarat*
[3]*NPD Officer, WalparNutritions Limited, Kalol,Gandhinagar,Gujarat*
[4]*Managing Director, Alteus Group of Companies, Gariahat , Kolkata*
[5]*Assistant Manager - Supply Chain, Alteus Group of Companies, Gariahat , Kolkata*
[6]*BDM,Tanishq Life Care, Sarkhej, Ahmedabad, Gujarat*
[7]*Regulatoy Affairs Officer, WalparNutritions Limited, Kalol,Gandhinagar,Gujarat*
[8]*Quality Assurance Officer, WalparNutritions Limited, Kalol,Gandhinagar,Gujarat*

Date of Submission: 25-09-2025 Date of Acceptance: 05-10-2025

ABSTRACT: The objective of this review was to compare calcium lysinate (an amino acid chelate) with usual care, comprising a control group given conventional calcium supplements (calcium carbonate or calcium citrate), as an intervention to prevent and treat postmenopausal osteoporosis. Osteoporosis is a systemic disease due to reduced bone strength, so the calcium supplementation is an important supplemental treatment. Conventional supplements are affected by problems with absorption in a pH-dependent manner, gastrointestinal intolerance and modest and controversial efficacy to reduce fracture risk. Calcium lysinate is proposed as a promising alternative based on 2 hypothesized mechanisms of action: 1) an increased bioavailability by active amino acid transport pathways and (2) direct organic bone matrix support through the provision of L-lysine, an essential collagen synthesis substrate. The sole clinical documentation of calcium lysinate comes from an exploratory study in osteopenic subjects, which noted a relative bioavailability increase (223.15%) and greater bone mineral density (BMD) improvement at 8 weeks vs conventional presentations.[14] However, the results should be interpreted cautiously in view of the small sample size, short follow-up and surrogate end points. Though conceptually preferable, at present there is no evidence from clinical trials of any effect of calcium lysinate on our primary outcome of fracture risk. The review concludes that calcium lysinate is an appealing but yet to be established candidate where the available evidence does not support a change in practice. Large-scale (long-term) randomized controlled trials are needed for confirmation of its efficacy and safety on fracture prevention, in order to be recognized as a definite substitute of standard supplements.

Key Words: Osteoporosis, Calcium Lysinate, Calcium Carbonate, Calcium Citrate, Bone Mineral Density, Bioavailability, Fracture Risk, Collagen Synthesis, Amino Acid Chelate, Supplementation.

I. INTRODUCTION

Osteoporosis is a common condition that causes bones to become fragile and prone to fractures.[2] Healthy bones need calcium because it's a key part of what bones are made of and helps them function well.[8] Therefore, calcium supplementation is generally second line in osteoporosis management when the dietary intake is not optimal. Long ago, calcium carbonate and calcium citrate were the mainstay of therapy. But current debate employs them particularly due to their moderate effectiveness, their variable bioavailability and GI side effects, as well as the possible future safety are a vivid matter of debate.[16] New formulations have been developed to circumvent these limitations. The latter has proved to be superior than organic calcium and from these, calcium lysinate an amino acid chelate has emerged as a promising choice. It is said to provide its maximum bio-availability and has a double-action system containing calcium for proper bone mineralization and the crucial amino acid L-lisina essential toward collagen formation.[14] The goal of the follow-up studies is to evaluate calcium lysinate vs common forms of calcium supplements taking into account evidence on the mechanism, biovailability, clinical efficacy and safety.

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 5 Sept - Oct 2025, pp: 820-831 www.ijprajournal.com ISSN: 2456-4494

II. THE PATHOPHYSIOLOGICAL LANDSCAPE OF OSTEOPOROSIS AND THE RATIONALE FOR CALCIUM SUPPLEMENTATION

Defining Osteoporosis as a Disease of Compromised Bone Strength

Osteoporosis is a systemic metabolic bone disease defined by compromised bone strength, which predisposes an individual to a significantly increased risk of fracture.[1] This reduction in bone strength is a composite of two primary factors: diminished bone mineral density (BMD) and a deterioration in bone quality, which encompasses its microarchitecture, turnover rate, and material properties.[1] Clinically, osteoporosis is often termed a "silent disease" because it typically remains asymptomatic until a fragility fracture occurs.[3] These fractures most commonly affect the hip, wrist, or spine and can lead to devastating consequences, including chronic pain, significant height loss, the development of a stooped posture known as thoracic kyphosis or "dowager's hump," and a marked increase in morbidity and mortality, particularly following a hip fracture.[3]

The Cellular Basis of Bone Loss: The Remodeling Imbalance

Remodeling of the bone Bone is a metabolically active, living tissue in which the bone constituents are continually renewed, called remodeling. This is an intricately responsive balance between the removal of old bone by osteoclasts and formation of new bone by osteoblasts.[2] Under physiological conditions of the adult skeleton, these two processes are balanced so as to maintain bone mass. The development of osteoporosis stems from a disruption of this balance, in which the rate of osteoclastic bone resorption overtakes that of osteoblastic bone formation, leading to the net loss in bone mass and structure.[1] This inequality becomes further exaggerated with age and is the main cause of morbidity among postmenopausal women. Reduction of estrogen levels during menopause is an major factor on this, since the lack of estrogen augments bone remodeling activity and leads to a larger net loss of bone per cycle.[1]

The Central Role of Calcium in Skeletal Homeostasis

As far as worth latching on to as a good role model for moral integrity, the epic poem of Beowulf is at the top. Over 99% of the total kidney stone body stored calcium is inside the skeleton in hydroxyapatite crystals form, so bone gets its rigidity and compressive strength.[8] Apart from its structural role, the skeleton is the body's main calcium reservoir which is life-supporting for ensuring that serum calcium concentrations remain within a narrow physiological range. This well-regulated state is essential for many systemic functions, including neuromuscular transmission, blood coagulation, and intracellular signaling.[8] The control of serum calcium is managed by a complex web of hormones, mainly including parathyroid hormone (PTH), 1,25 - dihydroxyvitamin D (calcitriol) and calcitonin. When the serum calcium level falls, the parathyroid glands release PTH, which has the effect on bones of inducing osteoclastic resorption thus sending calcium liberated from the skeletal repository into the blood stream to bring it back to normal levels.[7]

The Rationale for Supplementation: Mitigating Resorptive Stimuli

Long-term, low calcium intake is a recognised risk factor for poor bone health and osteoporosis.[4] When systemic calcium needs of the body cannot be met by diet, it is physiologically obliged to utilize the skeletal cauldron in order to maintain serum calcium homeostasis, with untoward consequences for bone masses.[13] Thus, the basic reason for calcium supplement in the treatment of osteoporosis is to maintain an adequate source of systemic calcium. This meets the non-skeletal requirements of, the body; this in its turn inhibits PTH release and decreases the principal hormonal incentive for bone resorption.[7]
It’s not anabolic Notably, this mechanism demonstrates that the major role of calcium supplementation is not anabolic (it doesn’t directly stimulate the creation of new bone, as drugs like teriparatide do).[15] It is predominantly anti-resorptive, however. Supplementation slows the rate of bone loss by relieving the physiological pressure to demineralize the skeleton.[16] Thus, the therapeutic goal of calcium supplementation in clinical practice should not be a dramatic rise in bone mass, but to counteract the loss and preserve pre-existing levels of bone strength.

III. AN EVIDENCE-BASED OVERVIEW OF CONVENTIONAL CALCIUM FORMULATIONS

To provide a benchmark for evaluating novel formulations, it is essential to first critically assess the most common forms of calcium supplements used in clinical practice. The choice

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 5 Sept - Oct 2025, pp: 820-831 www.ijprajournal.com ISSN: 2456-4494

among these conventional options is often guided by a balance of elemental calcium content, pharmacokinetic properties, and patient tolerability.

Calcium Carbonate: The High-Potency Standard

Calcium carbonate is the most commonly used and least expensive source of calcium available, primarily in part with its elemental weight percentage approaching about 40%.[17] This high potency provides dose-efficient nutrition, making it easier for patients to meet their daily intake requirements with fewer tablets. Its pharmacokinetic profile is highly limited, though. Calcium carbonate is not very soluble and can only be absorbed in an acid environment. For such reason, its bioavailability increases with food intake and a meal can induce gastric acid secretion.[17] This pH-dependency may paradoxically represent is an unsolved issue for elderly patients with potentially low gastric acid production (achlorhydria). In addition, calcium carbonate GROM is often linked to GI intolerance, primarily constipation, bloating and gas which can compromise long-term adherence.[22]

Calcium Citrate: The Acid-Independent Alternative

In particular patient groups, calcium citrate offers an important alternative. With 21% of the calcium being elemental, this means that a bigger pill or more frequency is required in order to obtain these same levels of elemental calcium as found in its carbonate kind. Its greatest advantage lies in superior solubility and acid-independent absorption. In patients with hypochlorhydria or those taking drugs like proton pump inhibitors, calcium citrate may be a better choice than the carbonate form.[17] Both if taken alone or with food, calcium citrate is absorbed quite well. Clinically, calcium citrate is generally better tolerated, causing fewer and milder gastrointestinal disturbances when compared to calcium carbonate which may increase patient compliance.[25] The choice between these two clinical options is therefore not governed by any clear superiority in long-term performance (such exists of course for both), but rather represents a pragmatic trade-off between the dose economy of carbonate and those patient-specific factors which influence absorptive capacity and chronic tolerability for citritin.

Other Formulations (e.g., Gluconate, Lactate, Phosphate)

Less commonly calcium gluconate, lactate or phosphate are also available for oral supplementation on a chronic basis in osteoporosis. They also contain much lower percentages of elemental calcium; 9% for calcium gluconate and 13% for calcium lactate, respectively.[19] Low-dose aspirin would allow long-term use, although its number of tablets required brought on a level of daily dose for osteoporosis prophylaxis that was unrealistic. For example, calcium gluconate is typically reserved for IV in the emergent treatment of symptomatic severe hypocalcemia.[27]

Overall Efficacy and Limitations of Conventional Supplements

However, the general effectiveness of traditional calcium preparations on rough clinical outcomes is a matter of intense debate. A number of meta-analyses of RCTs consistently show that calcium supplementation alone or with concomitant vitamin D produces only small and no progressive increases in BMD, usually averaging 0.6-1.8% over one to two years.[30] This marginal benefit does not seem to grow with increasing time of use.[32]

Concerning the most clinically relevant outcome on fracture risk reduction, this is even more controversial. Although a modest effect, especially with respect to hip fracture reduction in institutionalized older people treated with calcium and vitamin D 3, is evident from some meta-analyses, numerous other large studies have not observed any striking reduction of the risk of fractures in community-living adults.[11] In addition to gastrointestinal issues, long term safety concerns include risk for nephrolithiasis (kidney stones) and cardiovascular events including myocardial infarction.[16]

The continued debate and small effect can be considered as recognition that the role of calcium intervention has changed over time. At first this approach was considered as a main but now its role is more widely seen as a complementary adjunctive treatment. The treatment procedures of osteoporosis have changed markedly with the advent of very effective medications (bisphosphonates and biologics)[15]. Although some data suggest a calcium co-delivery-independent effect 11, practice guidelines all advocate attaining adequacy of calcium and vitamin D.[39] This implies that the major role of supplementation is to maintain sufficiency in calcium balance for secondary reasons with higher priority than sex steroid deficiency, thereby avoiding development

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 5 Sept - Oct 2025, pp: 820-831 www.ijprajournal.com ISSN: 2456-4494

of secondary hyperparathyroidism and setting the stage for the body's necessary mineral substrate to back up actions taken by more potent antiresorptive or anabolic therapies.

IV. CALCIUM LYSINATE: A NOVEL AMINO ACID CHELATE WITH A DUAL-ACTION HYPOTHESIS

Amidst the ongoing debate surrounding conventional calcium supplements, novel formulations have emerged that aim to improve bioavailability and potentially offer additional benefits for bone health. Among these, calcium lysinate, an amino acid chelate, presents a unique biochemical profile and a compelling mechanistic hypothesis that distinguishes it from simple calcium salts.

Biochemical Profile and Structure

Calcium lysinate is a coordination compound in which a central divalent calcium ion (Ca2+) is chemically bonded to two molecules of the essential amino acid L-lysine. This structure is formally known as Calcium di(L-lysinate) and has the chemical formula C12H26CaN4O4.[41] The formation of this stable chelate, where the mineral is bound within an organic molecule, is the foundation for its proposed advantages in absorption and its potential dual-action role in bone metabolism.[44]

Proposed Mechanism 1: Enhanced Calcium Bioavailability via Amino Acid Transport

The first component of calcium lysinate's proposed mechanism centers on superior absorption and retention. The chelation of calcium to lysine is theorized to protect the calcium ion from forming insoluble and unabsorbable complexes with dietary inhibitors like phosphates and phytates within the alkaline environment of the intestine.[14] More significantly, it is hypothesized that the intact calcium-lysine complex can be absorbed via active amino acid transport systems in the gut. This would allow it to bypass the traditional, often saturated, pathways for free calcium ion absorption, potentially leading to a more efficient uptake.[14] Furthermore, independent research has suggested that L-lysine itself may enhance calcium homeostasis by decreasing its urinary excretion, thereby improving the body's net retention of the calcium that is absorbed.[14]

Proposed Mechanism 2: Direct Support for Bone Matrix Synthesis

The second and possibly more unique aspect of the hypothesis concerns bone's organic matrix. Bone strength is not only determined by its mineral density, but also depends significantly on the quality and integrity of their organic trabecular network in which are defined mainly by structure and conserved volumes (90%.) type I collagen.[2] L-lysine is an essential constituent in the construction of such collagen network.[46] In the intricate series of events in collagen biosynthesis, certain lysine residues in procollagen peptides are hydroxylated by lysyl hydroxylase to hydroxylysine. This enzymatic step, for which vitamin C is a cofactor, is necessary for the subsequent formation of stable covalent cross-links that impart strength and stability to the collagen fibril network.[48] By combining calcium and L-lysine in the same molecular structure, calcium lysinate provides both the main mineral for hydroxyapatite formation and a major building block to form a strong organic matrix, as well as promise of both primary and secondary actions for bone health.

Critical Review of the Pivotal Clinical Trial (Sakthibalan et al.)

So far, the best clinical evidence to uphold these assumptions on calcium lysinate is provided by a single rater-blind, randomized pilot study by Sakthibalan et al.[44] This study investigated the bioavailability and effectiveness of calcium lysinate as compared to that of calcium carbonate and CCM during an 8-week intervention. The group of patients included in the study was composed by 24 patients with osteopenia (with T-score -1.0 to -2.5), but had osteoporosis.[14] A summary of findings and methodological considerations are provided in Table 2.

The analysis revealed two striking findings. First, from a comparison of the amount of calcemia in response to an acute vitamin D stimulation over 4.5 h only, we calculated a relative oral bioavailability of calcium lysinate (in AUC) as 223.15% in relation to the CaCO3 form.[14] Second, even though all 3 supplements significantly increased the calcaneal BMD T-score after 8 weeks, it was particularly higher in the calcium lysinate group ($P<0.004$).[14]

Although these findings are encouraging, they should be treated with caution. The published 223.15% bioavailability figure, although mechanistically possible with the chelate, may exaggerate the clinically relevant net level of calcium retention. The pharmacokinetic analysis

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 5 Sept - Oct 2025, pp: 820-831 www.ijprajournal.com ISSN: 2456-4494

time period of the study was short at 4.5 hours.[14] Rapid elevation of serum calcium was observed with calcium lysinate, whereas CCM has been reported to have a less rapid and more sustained bioavailability profile.[14] This brief period of measurement likely was within the range endpoint of the fast-acting lysinate but may have caused a truncation in the comparator absorption curve, resulting in an over-inflated RAUC value for lysinate. In addition, serum calcium is well-regulated homeostatically.[8] Rapid high spike in serum levels may induce compensatory reflex mechanisms, like increased renal excretion, to reestablish homeostasis. Thus, rapid serum rise does not necessarily result in twofold more calcium incorporation into bone and the biological effect of this quick uptake is also clinically unproved.

Table 2: Summary of the Randomized Clinical Trial of Calcium Lysinate vs. Comparators (Sakthibalan et al., 2019)

Parameter	Calcium Lysinate Group	Calcium Carbonate Group	Calcium Citrate Malate Group
Study Design	Randomized, Open-Label, Parallel-Group Pilot Study	Randomized, Open-Label, Parallel-Group Pilot Study	Randomized, Open-Label, Parallel-Group Pilot Study
Patient Population	Osteopenia (T-score -1.0 to -2.5)	Osteopenia (T-score -1.0 to -2.5)	Osteopenia (T-score -1.0 to -2.5)
Sample Size (n)	8	8	8
Duration	8 weeks	8 weeks	8 weeks
Primary Outcomes	Relative Bioavailability, Change in BMD T-score	Relative Bioavailability, Change in BMD T-score	Relative Bioavailability, Change in BMD T-score
Key Bioavailability Finding	**223.15% relative bioavailability vs. Carbonate**	Reference group (100%)	Not reported vs. Carbonate
Change in BMD T-score	Statistically significant improvement	Statistically significant improvement	Statistically significant improvement
p-value for BMD Change	**p<0.0004** (Most significant)	p<0.0042	p<0.0069
Reported Adverse Events	1 subject (abdominal bloating/belching)	3 subjects (abdominal bloating/belching)	1 subject (abdominal bloating/belching)

Data sourced from Sakthibalan et al..[14]

V. A HEAD-TO-HEAD COMPARATIVE ANALYSIS

Synthesizing the available evidence allows for a direct comparison of calcium lysinate with conventional supplements across several domains critical to clinical decision-making. This analysis highlights both the theoretical advantages of the

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 5 Sept - Oct 2025, pp: 820-831 www.ijprajournal.com ISSN: 2456-4494

novel chelate and the significant evidence gaps that currently limit its clinical application.

Table 1: Pharmacological and Physicochemical Properties of Oral Calcium Supplements

Property	Calcium Carbonate	Calcium Citrate	Calcium Lysinate
Chemical Form	Inorganic Salt	Organic Acid Salt	Amino Acid Chelate
Elemental Calcium (%)	**40%** (Highest)	21%	~11-20% (varies by preparation)
Solubility	Low; requires acid for dissolution	High; dissolves readily	High; chelated form
pH Dependency	**High** (absorption reduced in achlorhydria)	**Low** (absorption independent of gastric acid)	**Low** (absorbed via amino acid transporters, bypasses pH issues)
Optimal Intake	With food	With or without food	With or without food
Common GI Side Effects	Constipation, bloating, gas (most frequent)	Less frequent/milder constipation and gas	Infrequent; may be better tolerated
Key Advantages	High elemental content (fewer pills), low cost	Good absorption in elderly/on acid blockers, better GI tolerability	**Theoretically superior bioavailability, potential dual-action (collagen support)**
Key Disadvantages	Poor absorption without acid, high rate of GI side effects	Lower elemental content (more pills needed), higher cost	Limited clinical data, higher cost, lower elemental content than carbonate

Data compiled from sources.[14]

Bioavailability and Pharmacokinetics

The pilot study data suggest that calcium lysinate possesses a distinct pharmacokinetic profile, characterized by a significantly faster rate of absorption compared to its conventional counterparts. It achieved a 24% increase in serum calcium levels within 60 minutes, a stark contrast to the slower, more gradual rise observed with forms like calcium citrate malate.[14] This rapid absorption is consistent with the proposed mechanism of uptake via active amino acid transport systems, which would make its bioavailability more robust and less dependent on patient-specific factors like gastric pH—a key advantage over calcium carbonate.[21] Furthermore, the chelated structure of lysinate may prevent it from ionizing in the gut, which is claimed to reduce interference with the absorption of other essential minerals like iron, a theoretical benefit not offered by standard calcium salts.[14]

Clinical Efficacy on Bone Mineral Density

The reported efficacy of calcium lysinate on BMD is perhaps the most striking, and contentious, point of comparison. The pilot study demonstrated a highly significant improvement in calcaneal BMD in just 8 weeks.[14] This finding is anomalous when viewed against the extensive literature on conventional supplements. Meta-analyses of numerous large-scale trials show that BMD gains from calcium carbonate or citrate are small, in the range of 0.6-1.8%, and typically require one to two years to become apparent.[30] This major discrepancy raises critical questions: is the rapid and pronounced effect of calcium lysinate a genuine reflection of its dual-action mechanism, or is it an artifact of the study's limitations, such as its

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 5 Sept - Oct 2025, pp: 820-831 www.ijprajournal.com ISSN: 2456-4494

very small sample size and the use of calcaneal quantitative ultrasound, a less precise measurement technique than the "gold standard" dual-energy X-ray absorptiometry (DXA) scan?[52] The magnitude of the BMD effect reported for calcium lysinate is highly uncharacteristic for any calcium supplement acting alone.

Fracture Risk Reduction: The Evidence Gap

The ultimate goal of any osteoporosis therapy is the reduction of fracture risk. On this critical endpoint, the comparison is stark. For conventional supplements, there is a large, albeit controversial, body of evidence from numerous RCTs and meta-analyses assessing their effect on fracture incidence.[5] For calcium lysinate, there is currently no clinical trial data on the primary endpoint of fracture risk reduction. All claims for its efficacy are based on the surrogate endpoints of bioavailability and BMD changes from a single small study in osteopenic individuals. While some observational studies have linked higher dietary intake of certain amino acids, including lysine, to a lower risk of fracture [45], this association does not constitute direct evidence for the efficacy of a calcium lysinate supplement. This absence of fracture data is the single greatest limitation to its current clinical consideration.

Safety, Tolerability, and Adherence

In the pilot study, calcium lysinate appeared to be well-tolerated, with fewer reported gastrointestinal side effects (one subject) compared to calcium carbonate (three subjects).[14] This improved tolerability profile is consistent with that of other organic or chelated forms like calcium citrate [25] and could translate to better long-term patient adherence—a significant challenge with calcium carbonate and a crucial factor for achieving any potential long-term benefit.[22] However, the broader safety concerns associated with high-dose calcium supplementation, such as an increased risk of cardiovascular events and renal stones [24], must be assumed to apply to calcium lysinate until specific long-term safety data become available. The rapid spike in serum calcium observed with lysinate could theoretically pose a greater risk for vascular calcification than the slower, more gradual rise seen with other forms.[16]

The most compelling, albeit unproven, feature of calcium lysinate is its potential to address both the mineral and organic matrix components of bone strength. Bone strength is a function of both BMD and bone quality [1], with quality being largely determined by the collagen framework.[2] Conventional supplements only target the mineral component. By delivering both calcium for mineralization and L-lysine, an essential substrate for stable collagen cross-linking [46], calcium lysinate is the only formulation discussed that has the potential to improve both aspects of bone health. This "dual-action" hypothesis elevates it from simply being another vehicle for calcium delivery to a conceptually more holistic approach to nutritional bone support. This theoretical advantage is its key differentiator and provides the strongest justification for further rigorous investigation.

VI. SYNTHESIS, CLINICAL IMPLICATIONS, AND FUTURE RESEARCH DIRECTIONS

Summary of Evidence: A Promising Candidate with Preliminary Data

Calcium lysinate is an attractive formulation based on theoretical considerations for increased effectiveness in bone health that has been highlighted from this review. Its chelation is a feasible mechanism for facilitating better pH-independent absorption through amino acid transporters. It's special formulation of not only calcium but also L-lysine offers a dual-action possibility: bone mineralisation and the strength of collagen matrix. This hypothesis is suggested by the findings of one small pilot study in osteopenic subjects, which provided preliminary evidence for a very large superiority on both bioavailability and 1-week BMD change compared with calcium carbonate or calcium citrate malate.[14]

Nevertheless, this favorable picture needs to be interpreted in the light of the deeply inadequate underlying evidence. These data come from only one small, short-term, open-label study that was potentially susceptible to a methodologic bias which would have increased bioavailability levels and allocated the primary outcome to the BMD (a surrogate marker) and not to the clinically important end point of fracture reduction. This is a sharp contrast to the extensive but controversial literature on traditional supplements, which has, despite decades of research, demonstrated only small and inconsistent benefits; furthermorelongterm risks are also possibly involved. The proof on calcium lysinate is currently not enough to be conclusive and should be considered as hypothesis-generating.

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 5 Sept - Oct 2025, pp: 820-831 www.ijprajournal.com ISSN: 2456-4494

Clinical Implications and Recommendations

Given the present equilibrium of evidence, the potential of calcium lysinate remains as preliminary and unpublished to justify any alteration in current clinical practice for osteoporosis.

- "However, the first line of treatment is still 'food first,' as we like to say." This means advising patients to meet their daily calcium requirements (at least 1000 mg for men ages 51-70, and at least 1200 mg for women over 50 and men over 70) with food.[17]
- When dietary intake is inadequate and supplementation is indicated, however, the decision to use calcium citrate versus calcium carbonate will remain patient specific (eg, cost vs potential for achlorhydria or use of acid-blocking agents vs GI tolerability).
- It is important to view calcium as being adjunctive to an overall osteoporosis management strategy rather than the cornerstone of such a strategy. This encompasses evidence-based medications[15], achieving vitamin D sufficiency and introducing lifestyle changes including regular weight-bearing and muscle-strengthening activity.[3]

Unanswered Questions and a Call for Future Research

The interesting findings from the study of Sakthibalan et al. study underscore the pressing need for additional, stronger studies to confirm these preliminary results. The promise of calcium lysinate will be known only after a large, multicenter DBRCT. A trial of this nature is necessary to ascertain whether the theoretical benefits and initial potential translate into real clinical benefit.

There should be some key characteristics of a definitive trial:*

1. **Population:** The study must include postmenopausal women and men with established osteoporosis (T-score $ \le -2.5$), the population for whom fracture prevention is crucial.
2. **Key Outcome:** The primary endpoint should be the development of incident vertebral and non-vertebral fragility fractures in those followed for at least 3 to 5 years. That is the only endpoint that can confer genuine clinical utility.
3. **Secondary Endpoints:** The primary secondary endpoints are change in follow-up DEXA BMD at the hip and lumbar spine[52], changes in validated bone turnover markers and if feasible, newer methodologies to assess bone quality.
4. **Comparators:** Your trial will need to have a placebo comparator for establishing absolute efficacy, and an active comparator—such as calcium citrate plus vitamin D— should be used to evaluate relative efficacy.
5. **Safety Monitoring:** Adverse events should be closely monitored in an a priori fashion, with specific attention to cardiovascular outcomes and nephrolithiasis providing the major components of a safety profile.

Until such evidence is not available, calcium lysinate remains an intriguing but unproven alternative in the osteoporosis treatment armamentarium.

VII. RESULT

The comparison presents some important results. In regard to bioavailability, a pilot study found that calcium lysinate had an oral relative bioavailability of 223.15% in comparison with calcium carbonate with the peak concentration (Cmax) of serum Ca during a 4.5 hour observational period was statistically significantly faster and higher.[14] With regard to efficacy on surrogate marker of bone mineral density, it was the same study that also showed a significant improvement in WOMAC score in calcaneus BMD T-score over 8 wk in osteopenic patients; three test products tested (calcium lysinate, calcium carbonate and calcium citrate malate) showed statistically significant improvement. But the difference was largest for the calcium lysinate group ($p< 0.0004$).[14] This rapid, striking impact on BMD is paradoxical when compared to the many studies of standard supplements that find modest (0.6-1.8%) and slowly developing (1-2 years) increments in BMD. [30] Effects on the key clinical endpoint of fracture risk were similar for vitamin D with or without calcium, and there was no statistical suggestion of any heterogeneity of results (I^2 =4·9%, p=0·065; figure 3).[32] There is substantial evidence that calcium supplements have only a modest effect on fracture risk, which varies depending either on the total dose used28) or the other characteristics of an individual's diet.[33] The many meta-analyses including data from general populations26 consistently show no effect on fracture risk in both community-dwelling people

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 5 Sept - Oct 2025, pp: 820-831 www.ijprajournal.com ISSN: 2456-4494

and care home residents. 36 With regard to calcium lysinate, no clinical trial data are available on its effect in relation to fracture risk reduction. Regarding tolerability, there are preliminary data showing less gastrointestinal side effects for calcium lysinate than calcium carbonate.[14] Lastly, in terms of mechanism of action, calcium lysinate is theoretically distinctive as it has the potential for dual (bone mineralization and collagen matrix synthesis) rather than single mode (inorganic or organic salts of calcium) activity. [44]

VIII. CONCLUSION

Such dual-action hypothesis of a combination product is novel and has never been attempted with the use of conventional calcium supplements. This is suggested by initial data from one pilot study where better bioavailability and a greater short term change in BMD in osteopenic patients was observed. 44 However, there is currently only limited evidence to suggest that these can be said to have a significant therapeutic effect, the evidence base being far too weak and incomplete to provide any grounds for changing established treatment guidelines for osteoporosis. The good news comes from a small, short-term study with a surrogate endpoint, and there is absolutely no trial information on the most important clinical outcome: avoiding fractures. Accordingly, until large studies interim results are produced and double-blind randomized control trials are done to confirm these preliminary reports and prove a definite advantage in bone fracturing prevention, calcium lysinate remains an intriguing yet unconfirmed treatment. Future clinical practice must still emphasize the food-first method of absorbing calcium, with selective usage of traditional supplements such as calcium carbonate or citrate as adjuvant medicine to an all-inclusive osteoporosis control plan.

REFERENCES

[1]. Osteoporosis: Pathophysiology and therapeutic options - PMC - PubMed Central, accessed on September 16, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7415937/

[2]. Invited Review: Pathogenesis of osteoporosis | Journal of Applied Physiology, accessed on September 16, 2025, https://journals.physiology.org/doi/10.1152/japplphysiol.00564.2003

[3]. Osteoporosis: Practice Essentials, Background, Pathophysiology - Medscape Reference, accessed on September 16, 2025, https://emedicine.medscape.com/article/330598-overview

[4]. Osteoporosis - Symptoms and causes - Mayo Clinic, accessed on September 16, 2025, https://www.mayoclinic.org/diseases-conditions/osteoporosis/symptoms-causes/syc-20351968

[5]. Prevention of Fractures in Older People with Calcium and Vitamin D - PMC, accessed on September 16, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3257715/

[6]. Pathophysiology | International Osteoporosis Foundation, accessed on September 16, 2025, https://www.osteoporosis.foundation/health-professionals/about-osteoporosis/pathophysiology

[7]. Pathogenesis of osteoporosis: concepts, conflicts, and prospects - JCI, accessed on September 16, 2025, https://www.jci.org/articles/view/27071

[8]. Physiology, Calcium - StatPearls - NCBI Bookshelf, accessed on September 16, 2025, https://www.ncbi.nlm.nih.gov/books/NBK482128/

[9]. Calcium and phosphate: a duet of ions playing for bone health - PubMed, accessed on September 16, 2025, https://pubmed.ncbi.nlm.nih.gov/22081690/

[10]. Calcium Intake in Bone Health: A Focus on Calcium-Rich Mineral Waters - PMC, accessed on September 16, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6316542/

[11]. Calcium and Bone - PubMed, accessed on September 16, 2025, https://pubmed.ncbi.nlm.nih.gov/31792679/

[12]. Bone and calcium homeostasis - PubMed, accessed on September 16, 2025, https://pubmed.ncbi.nlm.nih.gov/1302303/

[13]. Calcium/Vitamin D Requirements, Recommended Foods & Supplements - Bone Health & Osteoporosis Foundation, accessed on September 16, 2025, https://www.bonehealthandosteoporosis.org/patients/treatment/calciumvitamin-d/

[14]. A Randomized Open-Label Clinical Study Comparing the Efficacy ..., accessed on September 16, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6343570/
[15]. Osteoporosis Medication: Calcium Metabolism Modifiers, Parathyroid Hormone Analogs, Selective Estrogen Receptor Modulator, Monoclonal Antibodies, Endocrine, Calcium Salts, Estrogen Derivatives, Vitamins, Fat-Soluble, Estrogens/Progestins, Estrogens/Progestins-HRT - Medscape Reference, accessed on September 16, 2025, https://emedicine.medscape.com/article/330598-medication
[16]. Should We Prescribe Calcium Supplements For Osteoporosis Prevention? - PMC, accessed on September 16, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3970298/
[17]. Calcium and calcium supplements: Achieving the right balance - Mayo Clinic, accessed on September 16, 2025, https://www.mayoclinic.org/healthy-lifestyle/nutrition-and-healthy-eating/in-depth/calcium-supplements/art-20047097
[18]. Comparison of Common Calcium Supplements - AAFP, accessed on September 16, 2025, https://www.aafp.org/pubs/afp/issues/2000/1015/p1895.html
[19]. Vitamin D and Calcium and Bioavailability of Calcium in Various Calcium Salts - PMC - PubMed Central, accessed on September 16, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10721582/
[20]. Calcium Supplementation - Osteoporosis Canada, accessed on September 16, 2025, https://osteoporosis.ca/calcium-supplementation/
[21]. All About Calcium Supplements - New York State Department of Health, accessed on September 16, 2025, https://www.health.ny.gov/publications/1980/index.htm
[22]. Calcium Carbonate Side Effects: Common, Severe, Long Term - Drugs.com, accessed on September 16, 2025, https://www.drugs.com/sfx/calcium-carbonate-side-effects.html
[23]. CALCIUM: Overview, Uses, Side Effects, Precautions, Interactions, Dosing and Reviews, accessed on September 16, 2025, https://www.webmd.com/vitamins/ai/ingredientmono-781/calcium
[24]. The good, the bad, and the ugly of calcium supplementation: a review of calcium intake on human health - PMC - PubMed Central, accessed on September 16, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6276611/
[25]. Calcium - Health Professional Fact Sheet, accessed on September 16, 2025, https://ods.od.nih.gov/factsheets/Calcium/HealthProfessional/
[26]. Common and Rare Calcium Citrate Side Effects You Should Know About - GoodRx, accessed on September 16, 2025, https://www.goodrx.com/well-being/supplements-herbs/calcium-citrate-side-effects
[27]. Calcium Gluconate - StatPearls - NCBI Bookshelf, accessed on September 16, 2025, https://www.ncbi.nlm.nih.gov/books/NBK557463/
[28]. Calcium Gluconate | Drug Lookup | Pediatric Care Online - AAP Publications, accessed on September 16, 2025, https://publications.aap.org/pediatriccare/drug-monograph/18/4993/Calcium-Gluconate
[29]. Calcium gluconate dosing, indications, interactions, adverse effects, and more, accessed on September 16, 2025, https://reference.medscape.com/drug/calcium-gluconate-344434
[30]. Calcium intake and bone mineral density: systematic review and meta-analysis - PubMed, accessed on September 16, 2025, https://pubmed.ncbi.nlm.nih.gov/26420598/
[31]. Microelements for bone boost: the last but not the least - PMC, accessed on September 16, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5318168/
[32]. Calcium intake and bone mineral density: systematic review and meta-analysis - The BMJ, accessed on September 16, 2025, https://www.bmj.com/content/351/bmj.h4183
[33]. Calcium plus vitamin D supplementation and risk of fractures: an updated meta-

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 5 Sept - Oct 2025, pp: 820-831 www.ijprajournal.com ISSN: 2456-4494

analysis from the National Osteoporosis Foundation, accessed on September 16, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4715837/

[34]. Calcium Supplement Use Is Associated With Less Bone Mineral Density Loss, But Does Not Lessen the Risk of Bone Fracture Across the Menopause Transition: Data From the Study of Women's Health Across the Nation | JBMR Plus | Oxford Academic, accessed on September 16, 2025, https://academic.oup.com/jbmrplus/article/4/1/e10246/7478862

[35]. Calcium Supplements and Risk of Cardiovascular Disease: A Meta-Analysis of Clinical Trials - MDPI, accessed on September 16, 2025, https://www.mdpi.com/2072-6643/13/2/368

[36]. Calcium Alone Does Not Reduce Hip Fracture Risk - USDA ARS, accessed on September 16, 2025, https://www.ars.usda.gov/news-events/news/research-news/2008/calcium-alone-does-not-reduce-hip-fracture-risk/

[37]. Evidence that calcium supplements reduce fracture risk is lacking - PubMed, accessed on September 16, 2025, https://pubmed.ncbi.nlm.nih.gov/20089500/

[38]. Calcium Supplementation- Efficacy and Safety - PMC, accessed on September 16, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11821691/

[39]. Clinician's Guide to Prevention and Treatment of Osteoporosis - PMC - PubMed Central, accessed on September 16, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4176573/

[40]. Dietary Calcium and Supplementation - StatPearls - NCBI Bookshelf, accessed on September 16, 2025, https://www.ncbi.nlm.nih.gov/books/NBK549792/

[41]. Calcium di(L-lysinate) | 6150-68-1 - Benchchem, accessed on September 16, 2025, https://www.benchchem.com/product/b1310256

[42]. Calcium di(L-lysinate) - Chemical Details, accessed on September 16, 2025, https://comptox.epa.gov/dashboard/chemical/details/DTXCID20132973

[43]. Calcium di(L-lysinate) | C12H26CaN4O4 | CID 6454211 - PubChem, accessed on September 16, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Calcium-di_L-lysinate

[44]. A Randomized Open-Label Clinical Study Comparing the Efficacy, Safety, and Bioavailability of Calcium Lysinate with Calcium Carbonate and Calcium Citrate Malate in Osteopenia Patients - ResearchGate, accessed on September 16, 2025, https://www.researchgate.net/publication/330698439_A_Randomized_Open-Label_Clinical_Study_Comparing_the_Efficacy_Safety_and_Bioavailability_of_Calcium_Lysinate_with_Calcium_Carbonate_and_Calcium_Citrate_Malate_in_Osteopenia_Patients

[45]. Association between amino acids and recent osteoporotic fracture: a matched incident case-control study - Frontiers, accessed on September 16, 2025, https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2024.1360959/full

[46]. L-Lysine for Collagen Production - Protein Works, accessed on September 16, 2025, https://www.theproteinworks.com/thelockerroom/l-lysine-for-collagen-production/

[47]. Collagen with Lysine and Vitamin C for Joint and Skin Health - Webber Naturals, accessed on September 16, 2025, https://webbernaturals.com/blogs/learn/collagen-with-lysine-and-vitamin-c-for-joint-and-skin-health

[48]. Collagen - Wikipedia, accessed on September 16, 2025, https://en.wikipedia.org/wiki/Collagen

[49]. A Randomized Open-Label Clinical Study Comparing the Efficacy, Safety, and Bioavailability of Calcium Lysinate with Calcium Carbonate and Calcium Citrate Malate in Osteopenia Patients - PubMed, accessed on September 16, 2025, https://pubmed.ncbi.nlm.nih.gov/30687654/

[50]. Calcium - Health Professional Fact Sheet - NIH Office of Dietary Supplements, accessed on September 16, 2025, https://ods.od.nih.gov/factsheets/Calcium-HealthProfessional/

[51]. Calcium Lysinate (Cas 75195-63-0) - Parchem, accessed on September 16, 2025, https://parchem.com/chemical-supplier-distributor/calcium-lysinate-000426
[52]. Bone Densitometry | Johns Hopkins Medicine, accessed on September 16, 2025, https://www.hopkinsmedicine.org/health/treatment-tests-and-therapies/bone-densitometry
[53]. Calcium intake: good for the bones but bad for the heart? An analysis of clinical studies, accessed on September 16, 2025, https://www.scielo.br/j/aem/a/ZZRyMPx9XJVPkpWmPVp9fpD/